Table 2.

Anti-proliferative activity represented by IC₅₀ values (μM)) of the three complexes in a panel of three human cell lines – 2 tumorigenic (HCT-116 and Caco-2) and one normal (CCD-18Co).

Complex	IC50 (μM)
	HCT-116			Caco-2
	24 h	48 h	72 h	24 h	48 h	72 h
1	25.4 ± 0.9	17.7 ± 2.2	13.1 ± 1.2	16.5 ± 2.2	7.7 ± 1.5	4.7 ± 1.1
2	49.9 ± 2.5	43.6 ± 2.1	30.1 ± 1.1	23.1 ± 2.1	18.7 ± 1.7	11.6 ± 1.1
3	79.0 ± 1.1	56.0 ± 1.7	32.1 ± 2.4	78.7 ± 5.3	58.0 ± 1.5	44.1 ± 3.6
Etoposide	28.9 ± 2.0	26.9 ± 1.5	14.3 ± 1.4	23.0 ± 0.9	18.9 ± 1.6	16.2 ± 1.7
	IC50 (μM)
	CCD-18Co
	24 h	48 h	72 h
1	54.0 ± 1.8	41.9 ± 1.9	55.4 ± 2.1
2	78.6 ± 2.1	60.6 ± 2.0	59.5 ± 2.5
3	80.9 ± 2.6	59.2 ± 2.6	42.9 ± 1.3
Etoposide	51.2 ± 1.1	48.7 ± 3.1	43.9 ± 1.8
Complex	IC50 (μM)
	HCT-116	TI*	Caco-2	TI*	CCD-18Co
	72 h		72 h		72 h
1	13.1 ± 1.2	4.22	4.7 ± 1.1	11.8	55.4 ± 2.1
2	30.1 ± 1.1	1.98	11.6 ± 1.1	5.14	59.5 ± 2.5
3	32.1 ± 2.4	1.33	44.1 ± 3.6	0.97	42.9 ± 1.3
Etoposide	14.3 ± 1.4	3.07	16.2 ± 1.7	2.71	43.9 ± 1.8

^*TI = therapeutic index = (IC₅₀)_CCD-18Co/(IC₅₀)_{cancer cells}